Pagaya Technologies Ltd. (PGY) Q3 2025 Earnings Call Transcript — Neutral

PGY   Seeking Alpha — November 10, 2025

Pagaya Technologies Ltd. ( PGY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Josh Fagen - Head of Investor Relations & COO of Finance Gal Krubiner - CEO, Co-Founder & Director Sanjiv Das - Co-Founder & President Evangelos Perros - Chief Financial Officer Conference Call Participants John Hecht - Jefferies LLC, Research Division Peter Christiansen - Citigroup Inc., Research Division Harold Goetsch - B.

image for news Pagaya Technologies Ltd. (PGY) Q3 2025 Earnings Call Transcript

YPF Sociedad Anónima (YPF) Q3 2025 Earnings Call Transcript — Neutral

YPF   Seeking Alpha — November 10, 2025

YPF Sociedad Anónima ( YPF ) Q3 2025 Earnings Call November 10, 2025 9:00 AM EST Company Participants Margarita Chun - Investor Relations Officer Horacio Marin - CEO & Non Independent Chairman Maximiliano Westen - Strategy, New Businesses and Controlling Vice President Pedro Kearney - Vice President of Finance Conference Call Participants Alejandro Anibal Demichelis - Jefferies LLC, Research Division Leonardo Marcondes - BofA Securities, Research Division Daniel Guardiola - Banco BTG Pactual S.A., Research Division Guilherme Costa Martins - Goldman Sachs Group, Inc., Research Division Tasso Vasconcellos - UBS Investment Bank, Research Division Presentation Margarita Chun Investor Relations Officer …

image for news YPF Sociedad Anónima (YPF) Q3 2025 Earnings Call Transcript

Repligen Corporation ( RGEN ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Jason Garland - CFO & Chief Compliance Officer Jacob Johnson - Vice President of Investor Relations Conference Call Participants Daniel Leonard - UBS Investment Bank, Research Division Presentation Daniel Leonard UBS Investment Bank, Research Division All right. With that, we're ready to kick things off.

image for news Repligen Corporation (RGEN) Presents at UBS Global Healthcare Conference 2025 Transcript

Cogent Biosciences, Inc. ( COGT ) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors November 10, 2025 8:00 AM EST Company Participants Christi Waarich - Senior Director of Investor Relations Andrew Robbins - President, CEO & Director Conference Call Participants Neeta Somaiah Anupam Rama - JPMorgan Chase & Co, Research Division Paul Jeng - Guggenheim Securities, LLC, Research Division Amanda Acosta-Ruiz - Leerink Partners LLC, Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Yuxi Dong - Jefferies LLC, Research Division Presentation Operator Good …

image for news Cogent Biosciences, Inc. (COGT) Discusses Positive Phase 3 PEAK Trial Results of Bezuclastinib in Gastrointestinal Stromal Tumors Transcript

For a company that practically prints cash, Amazon.com Inc. (NASDAQ:AMZN) might soon need Wall Street's help again. The e-commerce and cloud giant has not issued a major bond deal since 2021, when it raised $18.5 billion to fund the MGM acquisition — its last significant borrowing in over four years.

image for news Amazon's $150 Billion AI Capex Surge Could Force Its First Big Bond Deal In Years

MINNEAPOLIS , Nov. 10, 2025 /PRNewswire/ -- Northborne Partners is pleased to announce that it served as financial advisor to Tumac Lumber Company ("Tumac") in connection with the sale of its subsidiary, Disdero Lumber Company ("Disdero"), to BlueLinx Holdings ("BlueLinx"). Founded in 1953 and headquartered in Clackamas, Oregon, Disdero is a leading value-added wholesale distributor of a broad range of premium specialty forest products and other premium building materials used primarily in the construction of custom single-family homes and high-end multi-family residential projects.

image for news Northborne Partners Advises Disdero Lumber Company on its Sale to BlueLinx Holdings

As markets hit highs and AI stocks dominate the headlines, is the rally running on fumes? The Financial Prophet, Victor Dergunov, breaks down the risks of overheated technicals, stretched valuations, and the growing disconnect between Wall Street and the real economy.

image for news Lofty Valuations, Overheated Technicals - Managing Market Risk With Victor Dergunov

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, announces the filing of a class action lawsuit against Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) for violations of the federal securities laws on behalf of investors who purchased or acquired Baxter securities between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

image for news Lowey Dannenberg Notifies Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) Investors of Securities Class Action Lawsuit and Encourages Investors with more than $250,000 in Losses to Contact the Firm

AstraZeneca Plc (NASDAQ:AZN) shared on Monday full data from the Bax24 Phase 3 trial of once-daily 2mg baxdrostat versus placebo, on the reduction of ambulatory systolic blood pressure (SBP), as well as safety and tolerability in participants with resistant hypertension.

image for news AstraZeneca's Investigational Hypertension Drug Shows Significant Blood Pressure Control In Pivotal Trial

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dangerously high triglyceride (fat) levels.

image for news Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug

Can SoundHound's Q3 Growth Signal a New AI Profit Cycle? — Positive

SOUN   Zacks Investment Research — November 10, 2025

SOUN posts 68% revenue growth in the third quarter, raises guidance as enterprise AI demand fuels momentum toward breakeven in 2026.

image for news Can SoundHound's Q3 Growth Signal a New AI Profit Cycle?

Tyson Foods' Q4 Earnings Top Estimates, Sales Grow on Pricing — Positive

TSN   Zacks Investment Research — November 10, 2025

TSN posts a strong Q4 with higher earnings and sales driven by pricing gains, showcasing the strength of its diversified protein portfolio.

image for news Tyson Foods' Q4 Earnings Top Estimates, Sales Grow on Pricing

PNC Financial Plans 300+ Branches by 2030, Boosts Investment to $2B — Positive

PNC   Zacks Investment Research — November 10, 2025

PNC commits about $2B to open 300+ new branches by 2030, expanding in key U.S. markets and boosting community access.

image for news PNC Financial Plans 300+ Branches by 2030, Boosts Investment to $2B

Rigetti's New Orders and India MoU: Will They Boost Q3 Performance? — Positive

RGTI   Zacks Investment Research — November 10, 2025

RGTI secures $5.7M in Novera system orders and India MOU, but Q3 will test if momentum can turn into real revenue growth.

image for news Rigetti's New Orders and India MoU: Will They Boost Q3 Performance?

Can McCormick's CCI Savings Maintain EPS Momentum in 2025? — Positive

MKC   Zacks Investment Research — November 10, 2025

MKC leans on its CCI program savings to offset cost pressures and drive steady EPS growth in fiscal 2025.

image for news Can McCormick's CCI Savings Maintain EPS Momentum in 2025?

3 Stocks to Buy From a Prospering Electronics Components Industry — Positive

FN  NVT  TEL   Zacks Investment Research — November 10, 2025

The Zacks Electronics - Miscellaneous Components industry players like TEL, NVT and FN are benefiting from the solid adoption of AI and the democratization of IoT.

image for news 3 Stocks to Buy From a Prospering Electronics Components Industry

SAN DIEGO , Nov. 10, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Inspire Medical Systems, Inc. (NYSE: INSP) common stock between August 6, 2024 and August 4, 2025, both dates inclusive (the "Class Period"), have until January 5, 2026 to seek appointment as lead plaintiff of the Inspire Medical class action lawsuit. Captioned City of Pontiac Reestablished General Employees' Retirement System v.

image for news Robbins Geller Rudman & Dowd LLP Announces that Inspire Medical Systems, Inc. (INSP) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

KBR Investors with Losses Encouraged to Contact Hagens Berman Before Nov. 18th Deadline San Francisco, California--(Newsfile Corp. - November 10, 2025) - A pending class-action lawsuit targeting KBR, Inc. (NYSE: KBR) alleges that the company made misleading statements to investors in the weeks leading up to the abrupt cancellation of a major military contract which negatively impacted the company's business prospects. The lawsuit seeks to represent investors who purchased or otherwise acquired KBR securities between May 6, 2025 and June 19, 2025.

image for news KBR, Inc. (KBR) Cuts 2025 Revenue Due to TRANSCOM Termination, Securities Class Action Looms-Hagens Berman

Surgery Partners, Inc. (SGRY) Q3 2025 Earnings Call Transcript — Neutral

SGRY   Seeking Alpha — November 10, 2025

Surgery Partners, Inc. ( SGRY ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants David Doherty - Executive VP & CFO J. Evans - CEO & Director Conference Call Participants Brian Tanquilut - Jefferies LLC, Research Division Joanna Gajuk - BofA Securities, Research Division Benjamin Rossi - JPMorgan Chase & Co, Research Division Matthew Gillmor - KeyBanc Capital Markets Inc., Research Division Benjamin Hendrix - RBC Capital Markets, Research Division Andrew Mok - Barclays Bank PLC, Research Division Sarah James - Cantor Fitzgerald & Co., Research Division Benjamin Mayo - Leerink Partners LLC, Research Division William …

image for news Surgery Partners, Inc. (SGRY) Q3 2025 Earnings Call Transcript

Webcast Recording and Symposium Slides Now Available LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today hosted a compelling public webcast, where cancer key opinion leaders, principal investigators from the Phase 3 OVATION 3 and Phase 2 minimal residual disease (MRD) trials, clinicians, statistical experts and IMUNON executives shared critical insights into the disease and translational data, along with compelling clinical data highlighting the significant potential of IMNN-001 for women with advanced ovarian cancer.

image for news IMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer